

Michele Fabrazzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2505414/publications.pdf>

Version: 2024-02-01

52
papers

1,665
citations

279798

23
h-index

289244

40
g-index

53
all docs

53
docs citations

53
times ranked

2004
citing authors

#	ARTICLE	IF	CITATIONS
1	Obsessive-compulsive disorder with poor insight: A three-year prospective study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 323-330.	4.8	161
2	Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. <i>Psychiatry Research</i> , 1997, 71, 11-17.	3.3	130
3	Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co-morbid depression, psychopathology and hormonal variables. <i>Psychological Medicine</i> , 2005, 35, 897-905.	4.5	99
4	Opposite modifications in circulating leptin and soluble leptin receptor across the eating disorder spectrum. <i>Molecular Psychiatry</i> , 2002, 7, 641-646.	7.9	79
5	Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa. <i>Psychoneuroendocrinology</i> , 2005, 30, 243-250.	2.7	77
6	Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. <i>Biological Psychiatry</i> , 2005, 57, 926-931.	1.3	74
7	Ghrelin and leptin responses to food ingestion in bulimia nervosa: implications for binge-eating and compensatory behaviours. <i>Psychological Medicine</i> , 2003, 33, 1387-1394.	4.5	73
8	Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 1998, 13, 141.	1.7	70
9	Plasma Concentrations of Amino Acids in Chronic Schizophrenics Treated with Clozapine. <i>Neuropsychobiology</i> , 2001, 44, 167-171.	1.9	63
10	Pronounced Early Increase in Circulating Leptin Predicts a Lower Weight Gain During Clozapine Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 424-426.	1.4	60
11	Decreased Blood Levels of Tumor Necrosis Factor-Alpha in Patients with Obsessive-Compulsive Disorder. <i>Neuropsychobiology</i> , 1998, 37, 182-185.	1.9	59
12	Is the Time Course of Clozapine Response Correlated to the Time Course of Clozapine Plasma Levels? A One-Year Prospective Study in Drug-Resistant Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2002, 27, 1050-1055.	5.4	48
13	Plasma Leptin Response to Acute Fasting and Refeeding in Untreated Women with Bulimia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2499-2503.	3.6	47
14	Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: Contrasting anatomical and cellular localization. <i>Experimental Neurology</i> , 1995, 132, 33-41.	4.1	43
15	Opposite Changes in Circulating Adiponectin in Women With Bulimia Nervosa or Binge Eating Disorder. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5387-5391.	3.6	42
16	Central and Peripheral Peptides Regulating Eating Behaviour and Energy Homeostasis in Anorexia Nervosa and Bulimia Nervosa: A Literature Review. <i>European Eating Disorders Review</i> , 2014, 22, 307-320.	4.1	40
17	Depression in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2006, 26, 56-60.	1.6	39
18	Immunoendocrine Findings in Patients with Eating Disorders. <i>Neuropsychobiology</i> , 1999, 40, 115-120.	1.9	38

#	ARTICLE	IF	CITATIONS
19	Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 9-15.	2.4	36
20	Impaired glucose metabolism in bipolar patients and response to mood stabilizer treatments. <i>Journal of Affective Disorders</i> , 2019, 245, 174-179.	4.1	31
21	Fluvoxamine Increases Plasma and Urinary Levels of Clozapine and Its Major Metabolites in a Time- and Dose-Dependent Manner. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 708-710.	1.4	27
22	Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain. <i>Brain Research</i> , 1991, 542, 233-240.	2.2	26
23	Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias. <i>Psychiatry Research</i> , 2017, 256, 275-282.	3.3	25
24	Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. <i>Psychiatry Research</i> , 2014, 215, 263-267.	3.3	23
25	Did we learn something positive out of the COVID-19 pandemic? Post-traumatic growth and mental health in the general population. <i>European Psychiatry</i> , 2021, 64, 1-27.	0.2	22
26	Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients. <i>Neuropsychobiology</i> , 2015, 72, 29-36.	1.9	20
27	How to improve clinical practice on forced medication in psychiatric practice: Suggestions from the EUNOMIA European multicentre study. <i>European Psychiatry</i> , 2018, 54, 35-40.	0.2	20
28	Duration of untreated illness predicts 3-year outcome in patients with obsessive-compulsive disorder: A real-world, naturalistic, follow-up study. <i>Psychiatry Research</i> , 2021, 299, 113872.	3.3	20
29	A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. <i>European Psychiatry</i> , 2021, 64, e71.	0.2	20
30	Regulation of nerve growth factor receptor mRNA content by dexamethasone: In vitro and in vivo studies. <i>Neuroscience Letters</i> , 1990, 116, 216-220.	2.1	19
31	Comorbidity of Obsessive-Compulsive Disorder and Schizotypal Personality Disorder: Clinical Response and Treatment Resistance to Pharmacotherapy in a 3-Year Follow-Up Naturalistic Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 386.	2.6	18
32	Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study. <i>Brain Sciences</i> , 2020, 10, 483.	2.3	12
33	Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study. <i>European Neuropsychopharmacology</i> , 2012, 22, 132-136.	0.7	11
34	Social versus biological psychiatry: It's time for integration!. <i>International Journal of Social Psychiatry</i> , 2018, 64, 617-621.	3.1	11
35	Plasma Leptin Response to Acute Fasting and Refeeding in Untreated Women with Bulimia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2499-2503.	3.6	10
36	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 61.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Long-Term Treatment With Clozapine Does Not Affect Morning Circulating Levels of Allopregnanolone and THDOC in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 437-440.	1.4	9
38	Delirium and Cognitive Impairment as Predisposing Factors of COVID-19 Infection in Neuropsychiatric Patients: A Narrative Review. <i>Medicina (Lithuania)</i> , 2021, 57, 1244.	2.0	8
39	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. <i>Journal of Clinical Medicine</i> , 2021, 10, 5838.	2.4	8
40	The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients. <i>International Clinical Psychopharmacology</i> , 2019, 34, 206-210.	1.7	7
41	Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious Administration. <i>Clinical Schizophrenia and Related Psychoses</i> , 2019, 12, 185-188.	1.4	5
42	From over- to under-weight: treatment of post-surgical anorexia nervosa in morbid obesity. <i>Eating and Weight Disorders</i> , 2015, 20, 529-532.	2.5	4
43	Add-on oral olanzapine worsens hallucinations in schizoaffective disorder. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014205805-bcr2014205805.	0.5	3
44	Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature. <i>Brain Sciences</i> , 2021, 11, 1386.	2.3	3
45	Plasma Leptin and Antipsychotic-Induced Body Weight Gain. <i>Neuropsychopharmacology</i> , 2005, 30, 1769-1769.	5.4	2
46	Leucocytosis in clozapine-treated patients as predictor of loss of treatment response?. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014209148-bcr2014209148.	0.5	2
47	Internet-based field trials of the ICD-11 chapter on mental disorders. <i>World Psychiatry</i> , 2022, 21, 163-164.	10.4	2
48	A Multivariate Analysis of Depression Prevalence in Psoriasis Patients: A Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2060.	2.6	2
49	Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853). <i>Frontiers in Psychiatry</i> , 2022, 13, 833550.	2.6	2
50	Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case Reports. <i>Frontiers in Psychiatry</i> , 2022, 13, 868286.	2.6	1
51	A hypothesis on Cotard's syndrome as an evolution of obsessive-compulsive disorder. <i>International Review of Psychiatry</i> , 2021, 33, 23-28.	2.8	0
52	Klinefelter Syndrome: From a Disabling Condition to a Variant of Normalcy: Neuropsychiatric Aspects. <i>Trends in Andrology and Sexual Medicine</i> , 2020, , 77-83.	0.1	0